ClinicalTrials.gg
CompletedNCT06478563Updated Aug 11, 2025

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity

A Phase 1 interventional study of NNC0487-0111 (formulation D) and NNC0487-0111 (formulation C) in Obesity and Overweight, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
85th of 166
133 · median 138
Started
2024
with 21 others
Phase 1
85 of 207
22 open now
Registered
125th of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 85th largest by enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2024, is one of 85 in phase 1, and was the 125th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study consists of two phases: Phase A and Phase B. Participants are being asked to participate in both phases. Phase A of this study is comparing two formulations of a study medicine called NNC0487-0111 for weight control in people with overweight or obesity. Phase B of this study is testing how taking NNC0487-0111 at the same time as a meal affects the way NNC0487-0111 works in participants body. The aim of this study is to compare how two different formulations of NNC0487-0111 behave in the body, and how their function is affected when they are taken with or without a meal. Participants will either get NNC0487-0111 Formulation C, or NNC0487-0111 Formulation D. Both formulations are given as tablets. Which treatment participants get is decided by chance. Oral NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The study will last for about 5 - 6 months (155-184 days).

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 18-64 years (both inclusive)
  • (BMI) between 27.0 and 39.9 kilogram per meter square (kg/m\^2) (both inclusive)
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
  • Vitamin D (25-hydroxycholecalciferol) less than (\<) 12 ng/mL (30 Nanometer (nM)) at screening
  • Parathyroid hormone (PTH) outside normal range at screening
  • Total calcium outside normal range at screening
  • Calcitonin greater than or equal to (≥) 50 pg/mL at screening
  • Amylase greater than or equal to (≥) 2 times
  • Lipase greater than or equal to (≥) 2 times upper limit of normal
  • (HbA1c) greater than or equal to (≥) 6.5 % (48 millimoles per mole (mmol/mol)) at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Phase A: NNC0487-0111 (formulation D)

    Participants will receive once daily dose of six different dose levels (1-6) of NNC0487-0111 (formulation D) at increasing doses (the dose will be escalated every 3 weeks).

    Drug: NNC0487-0111 (formulation D)

  • Active comparator
    Phase A: NNC0487-0111 (formulation C)

    Participants will receive once daily dose of six different dose levels (1-6) of NNC0487-0111 (formulation C) at increasing doses (the dose will be escalated every 3 weeks).

    Drug: NNC0487-0111 (formulation C)

  • Experimental
    Phase B: NNC0487-0111 (formulation D)

    Participants will receive once daily dose of dose level 6 of NNC0487-0111 (formulation D).

    Drug: NNC0487-0111 (formulation D)

  • Active comparator
    Phase B: NNC0487-0111 (formulation C)

    Participants will receive once daily dose of dose level 6 of NNC0487-0111 (formulation C).

    Drug: NNC0487-0111 (formulation C)

Interventions

06

What researchers measure

Primary outcomes

  1. Phase A: The area under the NNC0487-0111 plasma concentration-time curve during a dosing interval at steady state

    Measured as hours\*nanomoles per liter (h\*nmol/L)

    Time frame: From pre-dose to after dosing on days 21, 42, 63, 84, 105 and 126

Secondary outcomes

  1. Phase A: The maximum observed plasma concentration of NNC0487-0111 at steady state

    Measured as nanomoles per liter (nmol/L)

    Time frame: From pre-dose to after dosing on days 21, 42, 63, 84, 105 and 126

  2. Phase A: The time from dose administration to maximum observed plasma concentration of NNC0487-0111 at steady state

    Measured as hours

    Time frame: From pre-dose to after dosing on days 21, 42, 63, 84, 105 and 126

  3. Phase B: The area under the NNC0487-0111 plasma concentration-time curve

    Measured as h\*nmol/L

    Time frame: From pre-dose to after dosing on day 132

  4. Phase B: The maximum plasma concentration of NNC0487-0111 after the last dose

    Measured as nmol/L

    Time frame: From pre-dose to after dosing on day 132

  5. Phase B: The time to maximum observed plasma concentration of NNC0487-0111 after the last dose

    Measured as hours

    Time frame: From pre-dose to after dosing on day 132

  6. Phase B:The terminal half-life of NNC0487-0111 after the last dose

    Measured as hours

    Time frame: From pre-dose on day 132 until completion of the end of study visit (day 153)

  7. Number of treatment emergent adverse events (TEAE)

    Measured as number of events

    Time frame: From time of trial product administration (Visit 2, day 1) until completion of the end of study visit (day 153)

07

Study locations

1 site
  • Celerion, Lincoln
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2025, 11 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 27, 2024
StartActual
Jun 27, 2024
Primary completionActual
Jun 5, 2025
CompletionActual
Jul 1, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06478563
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 27, 2024
Start date
Jun 27, 2024
Primary completion
Jun 5, 2025
Completion
Jul 1, 2025
Last update
Aug 11, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0487-0111

Start the discussion